Trials / Completed
CompletedNCT01889251
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
A Phase III Study of A01016 125μg Intravitreal Injection in Subjects With Symptomatic Vitreomacular Adhesion - Comparison Study to Sham Injection
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 251 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ocriplasmin | |
| DRUG | Sham injection |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2013-06-28
- Last updated
- 2015-11-30
- Results posted
- 2015-10-29
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01889251. Inclusion in this directory is not an endorsement.